.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Argus Health
Fuji
Cantor Fitzgerald
Farmers Insurance
Queensland Health
Dow
Harvard Business School
McKesson
UBS

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,589,552

« Back to Dashboard

Which drugs does patent 6,589,552 protect, and when does it expire?


Patent 6,589,552 protects TRICOR and is included in one NDA. There have been two Paragraph IV challenges on Tricor.

This patent has eighty-five patent family members in thirty-six countries.

Summary for Patent: 6,589,552

Title: Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Abstract:The invention provides fenofibrate compositions comprising granulates. The granulates can comprise micronized fenofibrate, inert hydrosoluble carrier particles, hydrophilic polymers, and, optionally, surfactants.
Inventor(s): Stamm; Andre (Griesheim, FR), Seth; Pawan (Irvine, CA)
Assignee: Laboratoires Fournier, S.A. (Dijon, FR)
Application Number:10/126,875
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-001Sep 4, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
Abbvie IncTRICORfenofibrateTABLET;ORAL021203-003Sep 4, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,589,552

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France97 00479Jan 17, 1997

Non-Orange Book Patents for Patent: 6,589,552

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,037,529Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
6,074,670 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
8,329,214Process for producing fenofibrate tablets► Subscribe
7,041,319Fenofibrate pharmaceutical composition having high bioavailabilty► Subscribe
6,652,881 Fenofibrate pharmaceutical composition having high bioavailability► Subscribe
6,596,317 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
6,277,405 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it► Subscribe
8,343,540Process for producing fenofibrate tablets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,589,552

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal952829► Subscribe
Portugal1275387► Subscribe
Slovakia285847► Subscribe
Portugal1273293► Subscribe
Slovakia96299► Subscribe
Russian Federation2238089► Subscribe
Poland194802► Subscribe
Poland334748► Subscribe
Norway20100034► Subscribe
New Zealand336462► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Cantor Fitzgerald
Fuji
Healthtrust
Teva
Merck
Queensland Health
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot